Dr. Williams is a seasoned biopharmaceutical executive with over 35 years of industry and academic expertise, including significant clinical management in multinational pharmaceutical companies like Incyte Corporation and GlaxoSmithKline. Dr. Williams has facilitated the entry of over 20 compounds into the clinic, including approvals for ruxolitinib (Jakafi) and baricitinib (Olumiant).

BriaCell is developing cell therapies for the treatment of advanced breast cancer and has promising compounds, including Bria-IMT, that are currently being evaluated in clinical trials. BriaCell recently received FDA approval for its Bria-IMT Combination pivotal study design in advanced metastatic breast cancer.

Tune into this episode to hear from Dr. Williams about BriaCell’s novel cell therapies for cancer and what the future of immunotherapy and personalized treatments may look like.

For more life science and medical device content, visit the Xtalks Vitals homepage.

Follow Us on Social Media

Twitter: @Xtalks

Instagram: @Xtalks

Facebook: https://www.facebook.com/Xtalks.Webinars/

LinkedIn: https://www.linkedin.com/company/xtalks-webconferences

YouTube: https://www.youtube.com/c/XtalksWebinars/featured